The purpose of this study is to evaluate efficacy, safety and tolerance of Beriplex® P/N compared with plasma in regard to rapid reversal of coagulopathy induced by coumarin derivatives in subjects who require immediate correction of INR because of emergency surgery or urgent invasive intervention.

• Biological: Beriplex® P/N
  Intravenous infusion, dosage depending on baseline INR, amount of coagulation factor IX and body-weight.
• Biological: Fresh frozen plasma
  Intravenous infusion, dosage depending on baseline INR and body weight

• Beriplex® P/N: Experimental
  Intervention: Biological: Beriplex® P/N
• Fresh frozen plasma: Active Comparator
  Intervention: Biological: Fresh frozen plasma

Inclusion Criteria:

• Male and female subjects ≥ 18 years,
• Subjects who have received oral anticoagulation therapy (e.g., warfarin, acenocoumarol or phenprocoumon) and in whom either an emergency surgical or an invasive intervention is indicated. Due to the nature of the procedure, withdrawal of anticoagulation therapy and plasma are also indicated,
• INR ≥ 2 within 3 hours before start of study treatment,
• Informed consent has been obtained.

Exclusion Criteria:

• Subjects with emergency surgical procedures in which, according to the surgeon's clinical judgment, an accurate estimate of blood loss is not possible (e.g., ruptured aneurysm).
• Administration of intravenous vitamin K more than 3 hours or administration of oral vitamin K more than 6 hours prior to infusion of study treatment,
• Expected survival of less than 3 days,
• Acute trauma for which reversal of vitamin K antagonists alone would not be expected to control an acute bleeding complication and/or control the acute bleeding event,
• History of thrombotic event, myocardial infarction, unstable angina pectoris, cerebral vascular accident, transient ischemic attack, severe peripheral vascular disease, disseminated intravascular coagulation within 3 months of enrolment,
• Known history of antiphospholipid antibody syndrome or lupus anticoagulant antibodies,
• Suspected or confirmed sepsis at time of enrolment,
• A previous thromboembolic event within 30 days prior to the inclusion into the study,
• Administration of whole blood, plasma, plasma fractions or platelets within 2 weeks prior to inclusion into study. Note: Administration of packed red blood cells is not an exclusion criterion,
• Pre-existing progressive fatal disease with a life expectancy of less than 2 months,
• Known inhibitors to coagulation factors II, VII, IX, or X; or hereditary protein C or protein S deficiency; or heparin-induced, type II thrombocytopenia,
• Treatment with any other investigational medicinal product within 30 days prior to inclusion into the study,
• Presence or history of hypersensitivity to components of study medication,
• Pregnant or breast-feeding women,
• Prior inclusion in this study or any other CSL Behring sponsored Beriplex study,
• For subjects with intracranial hemorrhage with:Glasgow Coma Score <10, modified Rankin Score > 3 prior to ICH,Intracerebral hemorrhage, Epidural hematomas, Infratentorial hemorrhage, Subarachnoid hemorrhage (SAH) subjects with a Hunt and Hess scale > 2, Subdural hematomas that:are judged to be an acute subdural hematoma (based on neurosurgeon review)or have a concurrent SAH or parenchymal contusion